The New England journal of medicine, 2020-02, Vol.382 (7), p.597-609
- Murthy, Rashmi K
- Loi, Sherene
- Okines, Alicia
- Paplomata, Elisavet
- Hamilton, Erika
- Hurvitz, Sara A
- Lin, Nancy U
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P
- Greil, Richard
- Cameron, David
- Carey, Lisa A
- Curigliano, Giuseppe
- Gelmon, Karen
- Hortobagyi, Gabriel
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Walker, Luke
- Feng, Wentao
- Winer, Eric P
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Murthy, Rashmi K
- Loi, Sherene
- Okines, Alicia
- Paplomata, Elisavet
- Hamilton, Erika
- Hurvitz, Sara A
- Lin, Nancy U
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P
- Greil, Richard
- Cameron, David
- Carey, Lisa A
- Curigliano, Giuseppe
- Gelmon, Karen
- Hortobagyi, Gabriel
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Walker, Luke
- Feng, Wentao
- Winer, Eric P
- Titel
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- Ist Teil von
- The New England journal of medicine, 2020-02, Vol.382 (7), p.597-609
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- In women with HER2-positive metastatic breast cancer who had previously received HER2-targeted therapy, tucatinib, a new selective inhibitor of the HER2 tyrosine kinase, was added to trastuzumab and capecitabine and compared with trastuzumab and capecitabine plus placebo. Progression-free survival at 1 year was 33% with tucatinib and 12% with placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1914609Titel-ID: cdi_proquest_journals_2354258648
- Format
- –
- Schlagworte
- Aged, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Brain cancer, Brain Neoplasms - secondary, Breast cancer, Breast Neoplasms - drug therapy, Breast Neoplasms - mortality, Breast Neoplasms - pathology, Cancer therapies, Capecitabine - administration & dosage, Capecitabine - adverse effects, Chemotherapy, Confidence intervals, Consolidation Chemotherapy, Diarrhea, Diarrhea - chemically induced, Double-Blind Method, Epidermal growth factor, ErbB-2 protein, Female, Humans, Immunotherapy, Kaplan-Meier Estimate, Laboratories, Magnetic resonance imaging, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Nausea, Oxazoles - administration & dosage, Oxazoles - adverse effects, Population, Progression-Free Survival, Protein-tyrosine kinase, Protein-Tyrosine Kinases - antagonists & inhibitors, Pyridines - administration & dosage, Pyridines - adverse effects, Quinazolines - administration & dosage, Quinazolines - adverse effects, Receptor, ErbB-2 - analysis, Receptor, ErbB-2 - antagonists & inhibitors, Survival, Targeted cancer therapy, Toxicity, Trastuzumab, Trastuzumab - administration & dosage, Trastuzumab - adverse effects, Tyrosine, Vomiting